Trial Profile
A Phase 3b, Randomized, Double-blind, Multicenter, Placebo Controlled, Dose Optimization, Crossover, Analog Classroom, Safety and Efficacy Study of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 01 Jun 2021 Planned End Date changed from 1 May 2011 to 4 May 2011.
- 01 Jun 2021 Planned initiation date changed from 1 Feb 2011 to 6 Mar 2011.
- 01 Jun 2011 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.